Showing 2881-2890 of 5771 results for "".
- Pykus Therapeutics to Present Initial Clinical Data on Novel Retinal Sealanthttps://modernod.com/news/pykus-therapeutics-to-present-initial-clinical-data-on-novel-retinal-sealant/2482651/Pykus Therapeutics announced that it will present initial clinical data on its investigational retinal sealant, PYK-2101, to replace gas and oil during retinal detachment repair. The data will be presented at the Vail Vitrectomy 2025 Meeting on February 10, 2025. The presentat
- CoFi Reaches New Milestone: 10,000 Vision Providers are Now Active on CoFi’s Multi-Party Payment Platformhttps://modernod.com/news/cofi-reaches-new-milestone-10000-vision-providers-are-now-active-on-cofis-multi-party-payment-platform/2482648/CoFi announced it has reached a new milestone of more than 10,000 ophthalmologists and optometrists active on the CoFi platform. Since CoFi’s commercial launch in the summer of 2021, the company has been growing rapidly, with nearly 200 new vision practices joining the platform each month i
- Iantrek Appoints Adam Szaronos as Chief Executive Officerhttps://modernod.com/news/iantrek-appoints-adam-szaronos-as-chief-executive-officer/2482644/Iantrek announced the appointment of Adam Szaronos as its new Chief Executive Officer. Mr. Szaronos succeeds company founder Sean Ianchulev, MD, MPH, who will remain as Chairman of the Board and Chief Medical Officer. “Iantrek has reached an exciting milestone as we transitio
- Rayner Completes Recruitment for RayOne Galaxy IDE Studyhttps://modernod.com/news/rayner-completes-recruitment-for-rayone-galaxy-ide-study/2482642/Rayner announced the closure of recruitment in the Investigational Device Exemption (IDE) study for the RayOne Galaxy IOL in the United States. Developed in collaboration with Brazilian ophthalmologist João Lyra, MD, PhD, RayOne Galaxy is the worl
- Study Demonstrates Efficacy of AI in Enabling Home OCT Monitoringhttps://modernod.com/news/study-demonstrates-efficacy-of-ai-in-enabling-home-oct-monitoring/2482641/Notal Vision announced the publication of pivotal study results evaluating the performance of its artificial intelligence (AI) algorithm designed to estimate key biomarkers in wet age-
- BVI Medical Launches Educational Platform for Ophthalmology Professionalshttps://modernod.com/news/bvi-medical-launches-educational-platform-for-ophthalmology-professionals/2482639/BVI Medical announced the launch of EyeXchange Solutions, a platform designed to enhance vision care through comprehensive educational resources and clinical support. This initiative aims to empower surgical decision-making, enhance provider experiences, alleviate economic
- Harrow Partners with Cencora to Launch “Harrow Cares” Programhttps://modernod.com/news/harrow-partners-with-cencora-to-launch-harrow-cares-program/2482637/Harrow announced the launch of its “Harrow Cares” program through a strategic partnership with Cencora. Harrow Cares is designed to deliver a suite of access and affordability services, enhancing support for retina specialists, their staff, and patients.
- SeaBeLife Reports Promising In Vivo Results for Ophthalmic Gel Candidate for GAhttps://modernod.com/news/seabelife-reports-promising-in-vivo-results-for-it-ophthalmic-gel-candidate-for-ga/2482635/SeaBeLife announced in vivo results for its SBL03 drug candidate, an ophthalmic gel designed to combat necrotic retinal cell death in geographic atrophy (GA). The primary objective of the preclinical study was to assess
- Norlase Receives FDA 510(k) Clearance and CE Mark for LYNX Pattern Scanning Laser Indirect Ophthalmoscopehttps://modernod.com/news/norlase-receives-fda-510k-clearance-and-ce-mark-for-lynx-pattern-scanning-laser-indirect-ophthalmoscope/2482634/Norlase announced the FDA 510(k) clearance and CE Mark for Norlase LYNX, which the company describes as the world’s first and only pattern scanning laser indirect ophthalmoscope. Commercially available now, the LYNX is battery-powered and provides surgeons the abili
- Outlook Therapeutics Presents Results from NORSE EIGHT Trial Evaluating ONS-5010 for the Treatment of Wet AMDhttps://modernod.com/news/outlook-therapeutics-presents-efficacy-and-safety-results-from-norse-eight-trial-evaluating-ons-5010-for-the-treatment-of-wet-amd/2482632/Outlook Therapeutics announced the presentation of data from NORSE EIGHT at the Hawaiian Eye and Retina 2025 Meeting. Baruch D. Kuppermann, MD, PhD, of Gavin Herbert Eye Institute, University of California, Irvine, CA presented the abstract titled, “ONS-5010 (bevacizumab-vikg